Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Non-Current Deffered Revenue (2024 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $145.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue changed N/A to $145.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $145.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $145.8 million for FY2025, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $145.8 million at Nuvation Bio, up from $144.6 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $145.8 million in Q4 2025, with the low at $7.9 million in Q3 2024.